GLP-1RA treatment effect in patients with T2DM and PAD

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Improved health status with SGLT2-inhibitor in HFrEF
Improved health status with SGLT2-inhibitor in HFrEF
AHA 2019
Improved health status with SGLT2-inhibitor in HFrEF
- Prof. Mikhail Kosiborod
Patients with moderate ischemia on a stress test do not need to go straight to the cathlab
Patients with moderate ischemia on a stress test do not need to go straight to the cathlab
AHA 2019
Patients with moderate ischemia on a stress test do not need to go straight to the cathlab
- Prof. Donald Lloyd-Jones
ARNI seems to give CV benefit not only in HFrEF, but up to EF of about 60%
ARNI seems to give CV benefit not only in HFrEF, but up to EF of about 60%
AHA 2019
ARNI seems to give CV benefit not only in HFrEF, but up to EF of about 60%
- Scott Solomon, MD
Is HF the same disease across the EF spectrum, or does HF have two physiologies that respond differently to treatment?
Is HF the same disease across the EF spectrum, or does HF have two physiologies that respond differently to treatment?
AHA 2019
Is HF the same disease across the EF spectrum, or does HF have two physiologies that respond differently to treatment?
- Prof. Lynne Stevenson